ClinicalTrials.Veeva

Menu

Lay Health Worker Led Symptom Assessment Intervention

Stanford University logo

Stanford University

Status

Completed

Conditions

Cancer

Treatments

Behavioral: Program participants

Study type

Observational

Funder types

Other

Identifiers

Details and patient eligibility

About

Rising costs and poor patient experiences from under-treated symptoms have led to the demand for approaches that improve patients' experiences and lower expenditures. This observational project assigned a lay health worker to conduct proactive symptom assessments intended to achieve these goals among patients with advanced cancer.

Full description

All newly diagnosed Medicare Advantage enrollees with Stage 3 or 4 solid tumors or hematologic malignancies who planned to receive all oncology care at the Oncology Institute of Hope and Innovation from 11/1/2015 through 9/30/2016 were enrolled in the program. The program consisted of a 12-month telephonic program in which a lay health worker (LHW) supervised on-site by a registered nurse practitioner (RNP), assessed patient symptoms after diagnosis using the validated Edmonton Symptom Assessment Scale (ESAS) with the frequency of symptom assessment varying based on patient risk. We evaluated feasibility, defined as monthly LHW documentation of symptom assessments, and change in patient-reported satisfaction and overall and emotional and mental health with validated assessments at enrollment and 5-months post-enrollment among patients in the intervention. We compared healthcare use and costs to a historical cohort of similar Medicare Advantage enrollees diagnosed between 11/1/2014-10/31/2015 (control). We assessed differences in demographic and clinical factors between the two groups using chi-square and t-tests and used generalized linear models to evaluate differences in healthcare use and costs.

Enrollment

288 patients

Sex

All

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Clinical diagnosis of stage 3 and 4 cancer
  2. Clinical diagnosis of hematologic malignancy
  3. Must receive care at the Oncology Institute of Hope and Innovation
  4. Must be an enrollee of CareMore Medicare Advantage

Exclusion criteria

None

Trial design

Trial documents
1

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems